Understanding the mechanisms of action of EGFR inhibitors in NSCLC: What we know and what we do not know

Lung Cancer

Volumn 41, Issue SUPPL. 1, 2003, Pages 15-22

  Raben, David ^a,c   Helfrich, Barb ^a   Ciardiello, Fortunato ^b   Bunn, Paul A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Angiogenesis; Chemotherapy; Epidermal growth factor receptor; Radiation; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PLATINUM;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RASH; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

EID: 0038012405     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00135-1     Document Type: Conference Paper

References (41)

1. Pavelic K., Banjac Z., Pavelic J., et al. Evidence for a role of EGF receptor in the progression of human lung carcinomas. Anticancer Res. 13:1993;1133-1137.
2. Rusch V., Klimstra D., Venkatraman E., et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in reversible non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3:1997;515-522.
3. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous lung carcinomas. Br. J. Cancer. 77:1998;663-669.
4. Fontanini G., De Laurentiis M., Vignati S., et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. 4:1998;241-249.
5. Olayioye M.A., Neve R.M., Land H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO. 19:2000;3159-3167.
6. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 3:1997;2703-2707.
7. Huang S.-M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6:2000;2166-2174.
8. Raben D., Helfrich B., Chan D., Bunn P.A. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung (NSCLC) cells in vitro and in vivo. Proc. Am. Soc. Clin. Oncol. 20:2001;257a.
9. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1999;1935-1940.
10. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7:2001;2958-2970.
11. Herbst R., Langer C. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 29:(1 Suppl 4):2002;27-36.
12. Dent P., Reardon D.B., Park Js., et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol. Biol. Cell. 10:1999;2493-2506.
13. Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6:2000;2166-2174.
14. Contessa J.N., Hampton J., Lammering G., et al. Ionizing radiation activated Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene. 21:2002;4032-4041.
15. Akimoto T., Hunter N.R., Buchmiller L., Mason K., Ang K.K., Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res. 5:1999;2884-2890.
16. Albanell J., Rojo F., Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin. Oncol. 28:(5 Suppl 16):2001;56-66.
17. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effects and potentiation of cytotoxic drugs: activity in human cancer cells by ZD1839 (Iressa), and epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 6:2000;2053-2063.
18. Sirotnak F., Zakowski M., Miller V., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6:2000;4885-4892.
19. Solomon B., Hagekyriakou J., Trivett M.K., Stacker S.A., McArthur G.A., Gullinane C. EGFR blockade with ZD1839 ('Iressa') potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 55:2003;713-723.
20. Bianco C., Tortora G., Bianco R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8:2002;3250-3258.
21. Huang S.M., Li J., Armstrong E.A., Harari P.M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 62:2002;4300-4306.
22. Ranson M., Hammond L.A., Ferry D., Kris M., et al. ZD 1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 20:(9):2002;2240-2250.
23. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:(21):2002;4292-4302.
24. Herbst R.S., Maddox A.M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20:(18):2002;3815-3825.
25. Fukuoka M., Yano S., Giaccone G., et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc. Am. Soc. Clin. Oncol. 21:2002;1188. Abstract.
26. Kris M.G., Natale R.B., Herbst R.S., et al. A phase II trial of ZD 1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol. 21:2002;1166. Abstract.
27. Bonomi P, Perez-Soler R, Chachoua A, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), CP-358, 774, following platinum-based chemotherapy in patients (pts) with advanced non-small-cell lung cancer (NSCLC). Proceedings of the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy 2000;11:(Abstract)386.
28. Garrison M.A., Tolcher A., McCreery H., et al. A phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 20:2001;283. Abstract.
29. Shin D.M., Nemunaitis J., Zinner R.G., et al. A phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 20:2001;324. Abstract.
30. Miller V., Johnson D., Heelen R.T., et al. A pilot trial demonstrates the safety and efficacy of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;326a. Abstract.
31. Giaccone G, Johnson DH, Manegold C, et al. Ann Oncol 2002;13(Suppl 5):Abs 4.
32. Johnson DH, Herbst R, Giaccone G., et al. Ann Oncol 2002;13(Suppl 5):Abs 468.
33. Raben D, Helfrich B, Chan D et al. The effects of ZD1839 (Iressa) on cell signaling processes and its growth effects with radiation and chemotherapy in human non-small cell lung cancer cells in vitro. Proceedings of the 12th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy 2001;12:(Abstract)153.
34. Sirotnak F., Zakowski M., Miller V., et al. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6:(12):2000;4885-4892.
35. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Can. 2:2002;683-693.
36. Viloria-Petit A., Crombet T., Jothy S., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vitro: a role for altered tumor angiogenesis. Cancer Res. 61:2001;5090-5101.
37. Chakravarti A., Loefler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62:2002;200-207.
38. Ciardiello F., Caputo R., Bianco R., et al. Cooperative inhibition of renal cancer growth by anti-epideraml growth factor receptor antibody and protein kinase A antisense oligonucleotide. J. Natl. Cancer Inst. 90:1998;1087-1094.
39. Ciardiello F., Bianco R., Damiano V., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 6:2000;3739-3747.
40. Normanno N., Campiglio M., De L.A., Somenzi G., et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13:2002;65-72.
41. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD 6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62:(16):2002;4645-4655.